Alacrita, Debiopharm Form Collaboration

MarketWatch reported that Alacrita, the trans-Atlantic life sciences consulting firm, and Debiopharm Group, the Swiss-based global biopharmaceutical company, have established an alliance to identify oncological, autoimmune, infectious diseases as well as metabolic in-licensing opportunities stemming from the Massachusetts life science cluster.

As quoted in the market news:

“Debiopharm’s resources and expertise in global pharmaceutical development make it an ideal partner for Massachusetts organizations looking to move their preclinical programs into clinical trials. Debiopharm has a track record of shepherding early stage pharmaceutical programs into late stage clinical trials and has demonstrated extraordinary success in delivering new medical breakthroughs to patients, a testament to its impressive preclinical, clinical, manufacturing, drug delivery, formulation and regulatory expertise,” said Alacrita partner Rob Johnson. “Alacrita is proud to have been selected by Debiopharm to source new in-licensing opportunities for the group and enable the next generation of medical products.”

Click here for the full press release on MarketWatch